Glofitamab plus lenalidomide for high‑risk relapsed or refractory mantle cell lymphoma after a BTK inhibitor

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single‑arm, open‑label phase 2 trial using a Simon two‑stage design to test the combination of intravenous glofitamab and oral lenalidomide in adults with high‑risk relapsed or refractory mantle cell lymphoma who have previously received a BTK inhibitor. Patients receive two 1000 mg doses of obinutuzumab before starting glofitamab, with glofitamab given IV and lenalidomide self‑administered orally during induction. The primary endpoint is best overall response rate at the end of induction assessed by PET/CT using Lugano criteria, and secondary aims include complete response rate, safety, and exploratory biomarker studies such as ctDNA and total metabolic tumor volume. Enrollment is restricted to adults 18–80 with ECOG ≤2 and at least one high‑risk feature, and the two‑stage design allows early stopping for lack of efficacy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* • Signed Informed Consent Forms

  * Age: \>= 18 to 80 years
  * Eastern Cooperative Oncology Group =\< 2
  * Diagnosis of MCL established by histologic assessment
  * Previously treated with at least one prior line of systemic therapy for mantle cell lymphoma.
  * Prior therapy have included a BTK inhibitor, including ibrutinib, zanubrutinib, obrutinib, acalabrutinib and various BTKi in clinical trials. BTki exposure is required, which include BTKi failure or intolerance. BTKi failure is defined as progression of disease during BTKi therapy or patients have progressed or relapsed after completing BTK inhibitor therapy
  * At least one high risk features as classified:

    * Blastoid/pleomorphic variants ✔ Ki67 ≥50% ✔ TP53 mutation or deletion
    * Bulky disease (defined as any lesion ≥7.5 cm on the screening computed tomography \[CT\] scan）
    * Patients that did not achieve a CR with their first-line treatment
    * early disease progression (POD24) ✔ patients with relapse and refractory treatment above 3 lines
  * Measurable lesions on cross-sectional imaging documented by diagnostic imaging(MRI, CT or PET-CT), （GTD）≥1.5 cm
  * Adequate liver function : Total bilirubin =\< 3 x upper limit of normal (ULN) (unless has Gilbert's disease), Aspartate aminotransferase (AST) =\< 5.0 x ULN, Alanine aminotransferase (ALT) =\< 5.0 x ULN

Exclusion Criteria:

* • Already enrolled in other Ongoing interventional or non-interventional R/R MCL clinical trials;

  * Currently receiving immunosuppressive treatment for other diseases;
  * Previous treatment with lenalidomide;
  * Combined with other malignant tumors within 3 years;
  * The researcher determines that they are not suitable to participate in this study;
  * Serious mental or neurological disorders that affect informed consent and/or the expression or observation of adverse reactions;
  * Have a history of major or extensive cardiovascular disease, such as New York Heart Association class III or Grade IV heart disease or objective assessment, myocardial infarction, unstable arrhythmia or unstable angina within 6 months before the first cycle;
  * Recent major surgery (within 4 weeks before the start of the first cycle);
  * Active autoimmune diseases with poor treatment control;
  * Any active infection that may affect the safety of the participant, including bacterial, fungal and various viral infections, occurred within 7 days before the first day of cycle 1;
  * Positive SARS-CoV-2 PCR test within 7 days prior to enrollment
  * Positive test results for chronic hepatitis B infection (defined as positive hepatitis B surface antigen \[HBsAg\] serology) Participants with occult or prior hepatitis B infection (defined as positive total hepatitis B core antibody and negative HBsAg) may be included if hepatitis B virus (HBV) DNA is undetectable at the time of screening. Such participants must be willing to undergo HBV DNA testing on Day 1 of every cycle and every 3 months for at least 12 months after the final cycle of study treatment and appropriate antiviral therapy as indicated.
  * Positive test results for hepatitis C (hepatitis C virus \[HCV\] antibody serology testing) Participants positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.
  * A history of severe deep vein thrombosis event or pulmonary embolism within 6 months
  * Patient follow-up was not possible.

Where it's running

• Peking University Third Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Hongmei Jing
• Email: hongmei_jing@163.com
• Phone: 86 010-82266781

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BTKi‑rituximab induction followed by glofitamab consolidation for high‑risk newly diagnosed mantle cell lymphoma

  This will test whether giving glofitamab after initial BTKi plus rituximab helps control high‑risk, newly diagnosed mantle cell lymphoma.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07257055

• Hypofractionated Radiotherapy plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL

  This study tests a combination therapy—hypofractionated radiotherapy with GM-CSF, pomalidomide, and glofitamab—for adults newly diagnosed with primary CNS DLBCL to see if it helps control the disease.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07749365

• Glofit-GemOx Bridging to Liso-cel for Relapsed/Refractory Large B-Cell Lymphoma

  This trial tests whether a bridging therapy with Glofit-GemOx followed by lisocabtagene maraleucel helps people with relapsed or refractory large B-cell lymphoma.

  Recruiting Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT07711483

• Glofitamab with R-CHOP for Newly Diagnosed HIV-Related Large B-Cell Lymphoma

  This phase 1 study tests glofitamab plus R-CHOP chemoimmunotherapy in adults newly diagnosed with HIV-related large B-cell lymphoma to see if the regimen is safe and tolerable.

  Recruiting Phase 1 National Cancer Institute (NCI) · Rockville, Maryland · NCT07649304

• Pola-ZR-Glo for older patients with large B‑cell lymphoma

  This trial will try combining polatuzumab vedotin, zanubrutinib, lenalidomide, and glofitamab as first-line treatment for people aged 70 and older with newly diagnosed large B‑cell lymphoma who are unfit for standard chemo or decline immunochemotherapy.

  Recruiting Phase 2 Ruijin Hospital · Shanghai · NCT07514169

• Glofitamab for mantle cell lymphoma after CAR-T failure

  This phase 2, multicenter, single-arm study tests glofitamab in adults with mantle cell lymphoma who did not respond to or relapsed after CAR-T cell therapy.

  Recruiting Phase 2 Fondazione Italiana Linfomi - ETS · Alessandria and 13 other locations · NCT07453095

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.